Published in PLoS One on September 12, 2008
Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology (2010) 1.82
Prediction of co-receptor usage of HIV-1 from genotype. PLoS Comput Biol (2010) 1.29
Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China. Retrovirology (2009) 1.10
Structural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop. PLoS One (2012) 0.91
Molecular dynamics simulation in virus research. Front Microbiol (2012) 0.87
Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge. PLoS One (2011) 0.83
Structural basis for specific recognition of substrates by sapovirus protease. Front Microbiol (2012) 0.83
Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc. PLoS One (2013) 0.82
Molecular evolution of HIV-1 CRF01_AE Env in Thai patients. PLoS One (2011) 0.81
Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism. Sci Rep (2013) 0.80
Electrophoretic mobility confirms reassortment bias among geographic isolates of segmented RNA phages. BMC Evol Biol (2013) 0.79
In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells. Front Microbiol (2016) 0.79
Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors. Retrovirology (2016) 0.76
Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1. Virol J (2011) 0.76
Molecular Dynamics Simulation of the Influenza A(H3N2) Hemagglutinin Trimer Reveals the Structural Basis for Adaptive Evolution of the Recent Epidemic Clade 3C.2a. Front Microbiol (2017) 0.75
Evolutionary Constraints on the Norovirus Pandemic Variant GII.4_2006b over the Five-Year Persistence in Japan. Front Microbiol (2017) 0.75
A Proposal for a Structural Model of the Feline Calicivirus Protease Bound to the Substrate Peptide under Physiological Conditions. Front Microbiol (2017) 0.75
Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics (1989) 73.50
Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol (1986) 36.06
DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics (2003) 32.63
The Amber biomolecular simulation programs. J Comput Chem (2005) 28.84
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
HIV-1 nomenclature proposal. Science (2000) 6.61
Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology (1991) 5.54
A new classification for HIV-1. Nature (1998) 5.30
Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol (1990) 5.20
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med (1997) 4.21
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol (1994) 3.70
The mathematical theory of communication. 1963. MD Comput (1997) 3.48
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol (1998) 3.23
A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci U S A (1997) 2.64
Causes of HIV diversity. Nature (1995) 2.48
Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts. Proc Natl Acad Sci U S A (1997) 2.35
V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol (1993) 2.27
Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses (2007) 2.19
Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury. J Infect Dis (1995) 1.79
Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun (1999) 1.75
Variance and covariances of the numbers of synonymous and nonsynonymous substitutions per site. Mol Biol Evol (1994) 1.57
Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS (1993) 1.54
Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5). Antimicrob Agents Chemother (2001) 1.41
N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J Virol (2000) 1.32
A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. J Virol (2007) 1.32
Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat Med (1999) 1.31
HIV type 1 V3 variation dynamics in vivo: long-term persistence of non-syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS. AIDS Res Hum Retroviruses (1997) 1.09
Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. AIDS (2002) 1.04
Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase. J Virol (2001) 1.03
Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism. J Virol (1999) 1.00
Isolation and characterization of replication-competent molecular DNA clones of HIV type 1 CRF01_AE with different coreceptor usages. AIDS Res Hum Retroviruses (2002) 0.95
Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop. Virology (1999) 0.89
Highly conserved configuration of catalytic amino acid residues among calicivirus-encoded proteases. J Virol (2007) 0.88
A group of V3 sequences from human immunodeficiency virus type 1 subtype E non-syncytium-inducing, CCR5-using variants are resistant to positive selection pressure. J Virol (2000) 0.86
Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet (2010) 2.74
Depression in Japanese patients with chronic obstructive pulmonary disease: a cross-sectional study. Respir Care (2012) 2.00
Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet (2013) 1.93
Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology (2004) 1.88
Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. Am J Hypertens (2004) 1.77
Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One (2011) 1.73
Estimation of 24-h urinary sodium excretion using lean body mass and overnight urine collected by a pipe-sampling method. J Hypertens (2002) 1.71
HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis (2005) 1.58
SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma (2010) 1.55
Impact of Corticosteroids on Mortality in Patients with Acute Respiratory Distress Syndrome: A Systematic Review and Meta-analysis. Intern Med (2015) 1.45
Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Res (2013) 1.45
The incidence of pre-eclampsia among couples consisting of Japanese women and Caucasian men. J Reprod Immunol (2006) 1.44
Multicenter validation of scoring system of pre-transplant serum ferritin and disease risk in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma (2012) 1.40
Accuracy of the pulse delay time technique with triple cuff for objective indirect blood pressure measurement. J Hypertens (2013) 1.40
Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol (2007) 1.40
Prognostic factors in diffuse large B-cell lymphoma treated by risk-adopted therapy. Intern Med (2006) 1.39
Henoch-Schönlein purpura in a patient with rheumatoid arthritis receiving etanercept. Eur J Dermatol (2010) 1.39
Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol (2010) 1.37
Behçet disease: evolution of clinical manifestations. Medicine (Baltimore) (2011) 1.33
A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. J Virol (2007) 1.32
Molecular analysis of magnetotactic bacteria and development of functional bacterial magnetic particles for nano-biotechnology. Trends Biotechnol (2007) 1.29
Identification of monomorphic and divergent haplotypes in the 2006-2007 norovirus GII/4 epidemic population by genomewide tracing of evolutionary history. J Virol (2008) 1.26
Japanese society of hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res (2003) 1.25
RanBPM, Muskelin, p48EMLP, p44CTLH, and the armadillo-repeat proteins ARMC8alpha and ARMC8beta are components of the CTLH complex. Gene (2007) 1.25
Pathology of asthma. Front Microbiol (2013) 1.25
The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol (2013) 1.23
Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica (2009) 1.22
Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat Struct Mol Biol (2008) 1.21
Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol (2011) 1.20
Risk factors for major limb amputations in diabetic foot gangrene patients. Diabetes Res Clin Pract (2005) 1.19
Cell-cycle-dependent regulation of human aurora A transcription is mediated by periodic repression of E4TF1. J Biol Chem (2002) 1.19
Molecular epidemiology of the heterosexual HIV-1 transmission in Kunming, Yunnan Province of China suggests origin from the local IDU epidemic. AIDS Res Hum Retroviruses (2005) 1.18
Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J Clin Microbiol (2011) 1.18
Identification of an insulator in AAVS1, a preferred region for integration of adeno-associated virus DNA. J Virol (2003) 1.18
Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infect Dis (2008) 1.16
Novel approach to fabricate porous gelatin-siloxane hybrids for bone tissue engineering. Biomaterials (2002) 1.16
Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. Proc Natl Acad Sci U S A (2013) 1.15
IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod (2006) 1.14
Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol (2007) 1.14
Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci (2011) 1.13
Human scribble, a novel tumor suppressor identified as a target of high-risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous polyposis coli. Genes Cells (2006) 1.13
Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer (2011) 1.13
Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lung prevents bleomycin-induced pulmonary fibrosis via a Fas-Fas ligand-independent pathway. Hum Gene Ther (2002) 1.12
Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther (2005) 1.11
Structural and functional characterization of the USP11 deubiquitinating enzyme, which interacts with the RanGTP-associated protein RanBPM. Biochem J (2002) 1.11
Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol (2010) 1.11
Neurological manifestations of Behçet's disease in Japan: a study of 54 patients. J Neurol (2010) 1.11
Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs. Arthritis Res Ther (2006) 1.11
Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1. Cancer Sci (2010) 1.10
Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol (2002) 1.10
Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast cancer cells. Int J Cancer (2006) 1.09
Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol (2007) 1.08
Mutational analysis of human papillomavirus type 16 major capsid protein L1: the cysteines affecting the intermolecular bonding and structure of L1-capsids. Virology (2003) 1.08
Heme oxygenase-1, a potential biomarker of chronic silicosis, attenuates silica-induced lung injury. Am J Respir Crit Care Med (2006) 1.08
Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res (2010) 1.08
European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci (2014) 1.08
Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine (2003) 1.07
Fatty acid chemistry at the oil-water interface: self-propelled oil droplets. J Am Chem Soc (2007) 1.07
Divergent evolution of norovirus GII/4 by genome recombination from May 2006 to February 2009 in Japan. J Virol (2010) 1.07
Bach1 regulates osteoclastogenesis in a mouse model via both heme oxygenase 1-dependent and heme oxygenase 1-independent pathways. Arthritis Rheum (2012) 1.06
Primary hepatic peripheral T-cell lymphoma treated with corticosteroid. Intern Med (2011) 1.06
Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data. Rheumatol Int (2011) 1.05